Underuse of inhaled steroid therapy in elderly patients with asthma.

Chest

Department of Medicine, Sunnybrook and Women's College Health Science Center, University of Toronto, Toronto, Ontario, Canada.

Published: March 2001

AI Article Synopsis

  • The study investigates the underuse of inhaled steroids in elderly asthma patients, revealing that 40% did not receive this treatment within 90 days post-hospitalization.
  • Older individuals (over 80 years) and those with multiple health conditions (Charlson comorbidity index > 3) were more likely to miss out on inhaled steroids.
  • Additionally, patients treated by primary-care physicians were at a higher risk of not receiving inhaled steroids compared to those seen by specialists like respirologists or allergists.

Article Abstract

Study Objectives: Despite their proven efficacy, inhaled steroids may be underused in the elderly asthmatic population. The objectives of this study were to determine if inhaled steroids are underused in the elderly asthmatic population, who are at a high risk for rehospitalization and mortality, and to identify certain risk factors that predict lower use of inhaled steroids in this group of patients.

Design: Population-based, retrospective, cohort study using linked data from hospital discharge and outpatient drug databases.

Participants: All people > or = 65 years old in Ontario, Canada, who survived an acute exacerbation of asthma between April 1992 and March 1997.

Measurements And Results: Of the 6,254 patients, 2,495 patients (40%) did not receive inhaled steroid therapy within 90 days of discharge from their initial hospitalization for asthma. Patients > 80 years old were at a greater risk of not receiving inhaled steroid therapy, compared to those 65 to 70 years of age (adjusted odds ratio [OR], 1.23; 95% confidence interval [CI], 1.05 to 1.47). Patients with a Charlson comorbidity index of > or = 3 were also at an increased risk of not receiving inhaled steroid therapy, compared to those having no comorbidities (adjusted OR, 3.45; 95% CI, 1.56 to 7.69). Moreover, receipt of care from a primary-care physician was independently associated with an elevated risk of not receiving inhaled steroid therapy, compared to receipt of care from respirologists/allergists (adjusted OR, 1.35; 95% CI, 1.10 to 1.61).

Interpretation: Forty percent of Ontario patients > or = 65 years old who experienced a recent acute exacerbation of asthma did not receive inhaled steroid therapy near discharge from their initial hospitalization for asthma. Nonreceipt of inhaled steroid therapy was particularly prominent in the older patients with multiple comorbidities. Moreover, those who received care from primary-care physicians were also less likely to receive inhaled steroid therapy, compared to those who received care from specialists.

Download full-text PDF

Source
http://dx.doi.org/10.1378/chest.119.3.720DOI Listing

Publication Analysis

Top Keywords

inhaled steroid
32
steroid therapy
32
therapy compared
16
inhaled steroids
12
receive inhaled
12
risk receiving
12
receiving inhaled
12
inhaled
10
steroid
8
therapy
8

Similar Publications

Comprehensive Review of Phthalate Exposure: Health Implications, Biomarker Detection and Regulatory Standards.

J Steroid Biochem Mol Biol

December 2024

Department of Applied Chemistry and Chemical Engineering, Islamic University, Kushtia-7003, Bangladesh; Institute of Glass and Ceramic Research and Testing(IGCRT), Bangladesh Council of Scientific and Industrial Research(BCSIR), Dhaka-1205, Bangladesh.

Phthalates are a wide family of chemicals that are used in many different industrial applications used in many different industrial applications, including the production of plastics, toys, food packaging particularly for kids, and medical equipment. Due to their various chemical and physical properties, phthalates may negatively impact humans, animals, and the environment. Thus the potential for phthalate exposure and harm to humans, animals, and the environment is high because its presence is alarming.

View Article and Find Full Text PDF

Objectives: To investigate the clinical implications of the obstructive pattern on plain chest radiography, defined as peribronchial cuffing or hyperinflation, in young children with severe lower respiratory tract infections (LRTIs).

Methods: We reviewed all children aged 3‒59 months with LRTIs who underwent radiography and polymerase chain reaction in a Korean emergency department from 2016 through 2020. The radiographs were read as consolidation, peribronchial cuffing, or hyperinflation, with each interrater reliability computed.

View Article and Find Full Text PDF

Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment.

Thorax

December 2024

Respiratory Medicine Unit and NIHR Oxford Biomedical Research Centre, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK

Macrolides reduce exacerbations when added to inhaled therapy in severe asthma. However, there is little published evidence for effectiveness in patients treated with biologics. We conducted a retrospective audit of all patients who started azithromycin while on biologics in our centre.

View Article and Find Full Text PDF

Background: We evaluated the inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β-agonist (ICS/LAMA/LABA) triple therapy with budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) versus dual LAMA/LABA and ICS/LABA therapies in patients with chronic obstructive pulmonary disease (COPD) and phenotypic features of asthma (bronchodilator reversibility and elevated blood eosinophils), but no asthma diagnosis, for whom treatment guidelines are limited.

Patients And Methods: KRONOS (NCT02497001) and ETHOS (NCT02465567) enrolled patients with moderate-to-very-severe COPD, no current asthma diagnosis, and either ≥0 (KRONOS) or ≥1 (ETHOS) moderate/severe exacerbations in the prior year. This pooled post hoc analysis evaluated trough forced expiratory volume in 1 second (FEV) and FEV area under the curve from hours 0 to 4 (AUC) change from baseline over 12-24 weeks, moderate/severe exacerbation rates, and St George's Respiratory Questionnaire (SGRQ) total score over 24 weeks with ICS/LAMA/LABA (BGF 320/14.

View Article and Find Full Text PDF

Background: Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function.

Objectives: The aim of the present study is to assess its effect after 1 year of treatment, focusing on airway inflammation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!